Statins and Venous Thrombosis: A Story Too Good to Be True?

PLoS Medicine

Volumn 9, Issue 9, 2012, Pages

  Rosendaal, Frits R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN;

ARTICLE; BLEEDING; BLOOD CLOTTING; CARDIOVASCULAR RISK; DEEP VEIN THROMBOSIS; HUMAN; INCIDENCE; LUNG EMBOLISM; META ANALYSIS (TOPIC); POSTTHROMBOSIS SYNDROME; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); VEIN THROMBOSIS;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; THROMBOEMBOLISM;

EID: 84866639045     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001311     Document Type: Article

References (14)

1. Rahimi K, Bhala N, Kamphuisen P, Emberson J, Biere-Rafi S, et al. (2012) Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med 9: e1001310 doi:10.1371/journal.pmed.1001310.
2. Rosendaal FR, (1999) Risk factors for venous thrombotic disease. Thromb Haemost 82: 610-619.
3. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, et al. (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5: 692-699.
4. Baglin T, Luddington R, Brown K, Baglin C, (2003) Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362: 523-526.
5. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR, (2005) Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293: 2352-2361.
6. United States Department of Health and Human Services (2008) The Surgeon's General call to action to prevent deep vein thrombosis and pulmonary embolism. Washington DC: United States Department of Health and Human services.
7. Wysowski DK, Nourjah P, Swartz L, (2007) Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 167: 1414-1419.
8. Åstrup T, (1958) The haemostatic balance. Thromb Diath Haemorrh (Stutt) 2: 347-357.
9. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, et al. (2000) Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann Intern Med 132: 689-696.
10. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, et al. (2001) Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 161: 1405-1410.
11. Ramcharan AS, van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, et al. (2009) HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 7: 514-520.
12. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2009) A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360: 1851-1861.
13. Thomsen RW, (2006) The lesser known effects of statins: benefits on infectious outcomes may be explained by "healthy user" effect. BMJ 333: 980-981.
14. Danaei G, Tavakkoli M, Hernan MA, (2012) Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 175: 250-262.